Exploring enterovirus pathogenesis and cancer therapy potential through reverse genetics

Area of Science:

• Virology
• Oncology
• Molecular Biology

Background:

• Oncolytic viruses are emerging as potent anticancer agents.
• Enteroviruses (EVs) exhibit specific tropism for tumor cells, making them attractive candidates for oncolysis.
• Reverse genetics has become a powerful tool for studying viral mechanisms and developing therapeutic applications.

Purpose of the Study:

• To review the progress and potential clinical applications of reverse genetics in the development of oncolytic enteroviruses.
• To explore the characteristics of EVs and the role of reverse genetics in understanding their infection mechanisms and oncolytic potential.
• To highlight specific enteroviruses with oncolytic roles and their significance in cancer immunotherapy.

Main Methods:

• Review of scientific literature on oncolytic enteroviruses and reverse genetics.
• Analysis of studies investigating enterovirus tropism and pathogenesis.
• Discussion of specific enterovirus serotypes with demonstrated oncolytic activity.

Main Results:

• Reverse genetics has significantly advanced the understanding of enterovirus infection mechanisms and pathogenesis.
• Specific enteroviruses, including EV-A71, CV-B3, Echo-7, CV-A21, and poliovirus, have shown oncolytic potential.
• The application of reverse genetics facilitates the development of engineered oncolytic enteroviruses for cancer therapy.

Conclusions:

• Oncolytic enteroviruses engineered using reverse genetics offer a promising avenue for cancer treatment.
• The tumor-specific tropism of certain EVs enhances their potential as targeted oncolytic agents.
• Further research and clinical translation of oncolytic EVs hold significant promise for cancer immunotherapy.